VIVO plc, a specialist clinical development partner and global leader in human challenge trials, focuses on accelerating vaccine and therapeutic development for major biopharma clients through ...
A recent paper in Nature Medicine explores how artificial intelligence could help select better matches among flu vaccine candidates. The influenza virus undergoes rapid genetic and phenotypic change ...
– INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection MELBOURNE, ...
VIVO plc (LSE:HVO) has been awarded a £6 million contract by a clinical-stage biopharmaceutical company to conduct an ...
Recently, Prof. Si Longlong's team from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences constructed a library of live-attenuated influenza A vaccines that utilize ...
Influenza A (H3N2) viruses appear to have entered a new phase of evolution. Analysis of more than 24,000 viral sequences revealed increasing diversification within clade J.2 and the emergence of a new ...
Substantial changes in disease progression were observed after a single oral dose of tivoxavir marboxil in the ferret model of bird flu using the A/Texas/37/2024 H5N1 virus isolated from an infected ...
A team of multi-specialty clinicians implemented the evidence-based Improving Vaccination Model at a pediatric pulmonary clinic and saw improved rates of vaccination administration and receptiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results